Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Adjuvant temozolomide Clear all
Terminated Phase 3 Interventional Results available

UNITE Study: Understanding New Interventions With GBM ThErapy

NCT03419403
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Steroid eye drops, Vasoconstrictor eye drops, Cold compress, Ophthalmic steroid ointment, Depatuxizumab mafodotin, Temozolomide, Radiation
Drug · Other · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

NCT01120639
View directory record Official record
Conditions
Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme
Interventions
Temozolomide, Stereotactic Radiosurgery (SRS)
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00770471
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, veliparib, DNA methylation analysis, gene expression analysis, mutation analysis, proteomic profiling, high performance liquid chromatography, immunoenzyme technique, laboratory biomarker analysis, mass spectrometry, pharmacogenomic studies, pharmacological study, adjuvant therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00486603
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
hydroxychloroquine, temozolomide, pharmacological study, Radiation
Drug · Other · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 23, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

NCT04397679
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy (IMRT), Temozolomide, Chloroquine, Tumor Treating Fields Therapy (TTF)
Radiation · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00390403
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
R-(-)-gossypol acetic acid, temozolomide, gene expression analysis, mutation analysis, protein expression analysis, laboratory biomarker analysis, pharmacological study, adjuvant therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT02715609
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Disulfiram, Copper Gluconate, Surgery, Radiation, Temozolomide
Drug · Procedure · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

NCT00200161
View directory record Official record
Conditions
Glioblastoma, Gliomas
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 23, 2026, 4:56 PM EDT
Active, not recruiting Phase 3 Interventional

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

NCT02685605
View directory record Official record
Conditions
Glioblastoma
Interventions
Standard surgery, Intraoperative radiotherapy, Radiochemotherapy, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
Universitätsmedizin Mannheim
Other
Eligibility
18 Years to 80 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Maywood, Illinois • Lake Success, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 23, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

NCT04195139
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Nivolumab, Temozolomide
Drug
Lead sponsor
University of Sydney
Other
Eligibility
65 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 23, 2026, 4:56 PM EDT
Recruiting Phase 2 Interventional

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

NCT05040360
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions
Capecitabine, Temozolomide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
446
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 23, 2026, 4:56 PM EDT
Suspended Phase 2 Interventional

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

NCT06202066
View directory record Official record
Conditions
Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm, Pancreatic Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant, Magnetic Resonance Imaging, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
Procedure · Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

NCT05781321
View directory record Official record
Conditions
Glioblastoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide, Biospecimen Collection
Radiation · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma

NCT00028795
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
202
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Sep 23, 2026, 4:56 PM EDT
Active, not recruiting Phase 3 Interventional

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

NCT00887146
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
271
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Recruiting Phase 3 Interventional

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

NCT07452458
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Radiation Therapy, Temozolomide, Temporally-modulated Pulsed Radiation Therapy
Procedure · Other · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
54
States / cities
Irvine, California • Los Angeles, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00869401
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
dasatinib, temozolomide, placebo, radiation therapy
Drug · Other · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
207
States / cities
Hartford, Connecticut • Jacksonville, Florida • Columbus, Georgia + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

NCT02903069
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma
Interventions
MRZ, TMZ, RT, Optune
Drug · Radiation · Device
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
La Jolla, California • Orange, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 23, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Radiation Therapy for Glioblastoma Multiforme

NCT01466686
View directory record Official record
Conditions
High Grade Glioma
Interventions
Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 23, 2026, 4:56 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762716
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Temozolomide (TMZ), Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

NCT04216329
View directory record Official record
Conditions
Gliosarcoma, Newly Diagnosed, Glioblastoma
Interventions
Selinexor, Temozolomide, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Olanzapine, Salt tablets, Anti-diarrheal
Drug · Radiation · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT02152982
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
390
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 23, 2026, 4:56 PM EDT
Not listed Phase 2 Interventional

Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas

NCT00492687
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, tamoxifen citrate, temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
San Diego Pacific Oncology & Hematology Associates
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 23, 2026, 4:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70

NCT01985087
View directory record Official record
Conditions
Glioblastoma
Interventions
Hypofractionated radiotherapy, Temozolomide
Radiation · Drug
Lead sponsor
University of Louisville
Other
Eligibility
70 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 23, 2026, 4:56 PM EDT